| Literature DB >> 25060415 |
Apurva O Badheka1, Nileshkumar J Patel2, Peeyush M Grover3, Neeraj Shah2, Nilay Patel1, Vikas Singh3, Abhishek J Deshmukh4, Kathan Mehta5, Ankit Chothani6, Ghanshyambhai T Savani3, Shilpkumar Arora1, Ankit Rathod7, George R Marzouka3, James Lafferty2, Jawahar L Mehta4, Raul D Mitrani8.
Abstract
Many medications used to treat atrial fibrillation (AF) also reduce blood pressure (BP). The relation between BP and mortality is unclear in patients with AF. We performed a post hoc analysis of 3,947 participants from the Atrial Fibrillation Follow-Up Investigation of Rhythm Management trial. Systolic blood pressure (SBP) and diastolic blood pressure (DBP) at baseline and follow-up were categorized by 10-mm Hg increments. The end points were all-cause mortality (ACM) and secondary outcome (combination of ACM, ventricular tachycardia and/or fibrillation, pulseless electrical activity, significant bradycardia, stroke, major bleeding, myocardial infarction, and pulmonary embolism). SBP and DBP followed a "U-shaped" curve with respect to primary and secondary outcomes after multivariate analysis. A nonlinear Cox proportional hazards model showed that the incidence of ACM was lowest at 140/78 mm Hg. Subgroup analyses revealed similar U-shaped curves. There was an increased ACM observed with BP <110/60 mm Hg (hazard ratio 2.4, p <0.01, respectively, for SBP and DBP). In conclusion, in patients with AF, U-shaped relation existed between BP and ACM. These data suggest that the optimal BP target in patients with AF may be greater than the general population and that pharmacologic therapy to treat AF may be associated with ACM or adverse events if BP is reduced to <110/60 mm Hg.Entities:
Mesh：
Substances：
Year: 2014 PMID： 25060415 DOI： 10.1016/j.amjcard.2014.06.002
Source DB: PubMed Journal: Am J Cardiol ISSN： 0002-9149 Impact factor: 2.778